Phase 3 Clinical Trials

Alkermes Pushes Narcolepsy Program to Phase III With Highly Competitive Mid-Stage Data

3 days ago talkbio0Tagged alixorexton, Alkermes, clinical endpoints, Narcolepsy, Orexin Receptor Agonist, Phase 2 Clinical Trials, Phase 3 Clinical Trials, Sleep Disorders, Wakefulness

Alkermes; alixorexton; narcolepsy; Phase II trial; Phase III clinical trial; orexin 2 receptor agonist; wakefulness; sleep disorder; clinical endpoints

Ionis Claims Curative Potential for Tryngolza in Severe Triglyceride Disease

6 days ago talkbio0Tagged Antisense Oligonucleotides, curative potential, Hypertriglyceridemia, Ionis, Pancreatitis, Acute, Phase 3 Clinical Trials, RNA-targeted therapy, Severe (severity modifier), Submission, Triglycerides, TRYNGOLZA, United States Food and Drug Administration

Ionis; Tryngolza; severe hypertriglyceridemia; curative potential; triglyceride reduction; acute pancreatitis; antisense oligonucleotide; FDA submission; Phase III trial; RNA-targeted therapy

AstraZeneca Makes Strong Case for Baxdrostat with Detailed 24-Hour Data in Resistant Hypertension Trial

6 days ago talkbio0Tagged 24-Hour Data, aldosterone synthase inhibitor, AstraZeneca, baxdrostat, Blood Pressure, blood pressure ambulatory, Phase 3 Clinical Trials, Resistant hypertensive disorder, safety profile

AstraZeneca; baxdrostat; resistant hypertension; phase III trial; aldosterone synthase inhibitor; blood pressure; 24-hour data; ambulatory blood pressure; safety profile

Lilly Prepares Amylin-Based Obesity Drug Eloralintide for Phase III After Strong Weight Loss Results

1 week ago talkbio0Tagged Agonist, Amylin, Clinical Development, Eli, Eli Lilly, Eloralintide, Obesity Drug, Phase 3 Clinical Trials, Weight Loss

Eli Lilly; eloralintide; amylin agonist; obesity drug; Phase III trial; weight loss; clinical development

Expert Flags Potential ‘Honeymoon Effect’ as Rapport Heads Towards Phase III Epilepsy Trials

2 weeks ago talkbio0Tagged Biological Markers, drug-resistant focal seizures, Epilepsy, Honeymoon Effect, KOL Bulletin, mid-stage, Phase 3 Clinical Trials, RAP-219, Rapport Therapeutics, Seizures

KOL Bulletin; honeymoon effect; Rapport Therapeutics; RAP-219; Phase III trials; epilepsy; drug-resistant focal seizures; seizure reduction; mid-stage data; biomarker

Intellia Pauses Two CRISPR Trials After Severe Liver Toxicity Hospitalizes Patient

3 weeks ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Hospitalization, Intellia, Liver, Pauses, Phase 3 Clinical Trials, Safety, Senile cardiac amyloidosis, Toxicity aspects

Intellia Therapeutics; CRISPR; transthyretin amyloidosis; Phase III trials; gene editing; liver toxicity; patient hospitalization; safety pause

Mixed Results for Roche’s Vamikibart in Phase III Uveitic Macular Edema Trials

4 weeks ago talkbio0Tagged central subfield, Clinical Relevance, MEERKAT trial, ocular adverse events, Phase 3 Clinical Trials, Roche (company), SANDCAT trial, Thick, uveitic macular edema, Vamikibart, vision improvement

Roche; vamikibart; uveitic macular edema; Phase III trials; MEERKAT trial; SANDCAT trial; vision improvement; central subfield thickness; clinical significance; ocular adverse events

SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented at ESMO 2025

4 weeks ago talkbio0Tagged Antibody-Drug Conjugates, BL-B01D1 - 303, Epidermal Growth Factor Receptor, iza-bren, Nasopharyngeal carcinoma, ORR, Phase 3 Clinical Trials, SystImmune

SystImmune; iza-bren; BL-B01D1-303; Phase III trial; nasopharyngeal carcinoma; dual primary endpoints; ORR; antibody-drug conjugate (ADC); EGFR×HER3 bispecific; ESMO 2025

Kailera Raises $600 Million to Launch Global Phase III Program for Obesity Drug

1 month ago talkbio0Tagged Bain Capital, clinical pipeline, Funding, GLP-1/GIP Dual Agonist, Kailera, Obesity Drug, Phase 3 Clinical Trials, Series B financing, weight loss therapy

Kailera; obesity drug; Phase III clinical trial; KAI-9531; GLP-1/GIP dual agonist; Series B financing; Bain Capital; weight loss therapy; clinical pipeline; biotech funding

Star Therapeutics Raises $125M as Bleeding Disorder Therapy Enters Phase III

2 months ago talkbio0Tagged Antibody Therapy, Blood Coagulation Disorders, Infrequent, Phase 3 Clinical Trials, Series D financing, Star Therapeutics, VGA039

Star Therapeutics; Series D financing; bleeding disorders; VGA039; Phase III clinical trial; biotech funding; rare diseases; antibody therapy